<DOC>
	<DOC>NCT02653131</DOC>
	<brief_summary>The inhibition of Dipeptidyl peptidase-4 should increase the concentration of glucagone-like peptide 1 and 2, and the increase of the latter should increase the absorptive capacity of the intestine.</brief_summary>
	<brief_title>The Use of DPP-4 Inhibitors in Short Bowel Syndrome</brief_title>
	<detailed_description>The only effective (to some extend drug) in short bowel syndrome is Glucacone-like peptide 4. Its price is, however, to high to really change the treatment strategy for intestinal failure. The Dipeptidyl peptidase-4 inhibitor, which a drug which is commonly used in the treatment of diabetes mellitus type II, should increase the concentration of glucagone-like peptide 1 and 2, and the increase of the latter should increase the absorptive capacity of the intestine.</detailed_description>
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Short Bowel Syndrome</mesh_term>
	<mesh_term>Dipeptidyl-Peptidase IV Inhibitors</mesh_term>
	<criteria>patients receiving home parenteral nutrition (HPN) because of short bowel syndrome for at least 12 months stable metabolic status benign disease HPN &lt; 12 months metabolically unstable cancer as the reason for intestinal failure</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>December 2016</verification_date>
	<keyword>Short bowel syndrome</keyword>
</DOC>